Effectiveness of Postoperative Adjuvant Radiotherapy in Atypical Meningioma Patients After Gross Total Resection: A Meta-Analysis Study

Lingzhe He†, Buyi Zhang†, Jianmin Zhang*, Zhige Guo†, Feina Shi and Qiang Zeng*

1 Department of Neurosurgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 2 Department of Neurology, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, China

Background: It still remains unclear whether patients with atypical meningioma (AM) could benefit from postoperative adjuvant radiotherapy (PORT) after gross-total resection (GTR).

Objective: Exploring the effectiveness of PORT on AM patients after GTR.

Methods: Literatures on PubMed, Embase, Web of science, and Scopus databases published between January 2000 and January 2019 were searched. After the selection based on the certain exclusion criteria, the Newcastle-Ottawa evaluation scale was used to evaluate the quality of the included literatures. Finally, a meta-analysis was conducted to analyze the effectiveness of PORT on local control (LC), progression-free survival (PFS) and overall survival (OS) in atypical meningioma patients after GTR.

Results: A total of 17 articles with 2,008 AM patients were included in the meta-analysis. The 5-year LC, 5-year PFS, and 5-year OS rates were 82.2, 84.1, and 79.0%, respectively, for AM patients receiving PORT after GTR, and they were 71.0, 71.9, and 81.5%, respectively, for those not receiving PORT after GTR. PORT could significantly improve 5-year LC rate (OR [95% Cl] = 2.59 [1.40–4.81], P = 0.002) and 5-year PFS rate (OR [95% Cl] = 1.99 [1.35–2.95], P = 0.001), but did not significantly improve 5-year OS rate (OR [95% Cl] = 1.07 [0.60–1.91], P = 0.828).

Conclusion: PORT could improve the 5-year LC rate and 5-year PFS rate in AM patients after GTR. AM patients might benefit from PORT after GTR.

Keywords: atypical meningioma, radiotherapy, gross-total resection, surgery, prognosis
INTRODUCTION

Meningiomas are the most common primary intracranial tumors with an incidence rate of about 8 per 100,000 population, accounting for approximately 37% of all central nervous system tumors (1). According to WHO 2016 classification, it can be divided into WHO grades I–III (2).

Compared to benign meningiomas (WHO grade I), atypical meningiomas (WHO grade II) have a more aggressive behavior, a higher risk of recurrence (seven to eight times increased in 5 years) and a higher mortality (3–5). Therefore, it is particularly important to find out the factors which could significantly influence the prognosis of AM patients. The common consensus is that postoperative adjuvant radiotherapy (PORT) is generally recommended for meningioma patients underwent subtotal resection (STR). Whether AM patients need PORT after GTR depends on the grade of meningiomas (6). After GTR, follow-up observation is generally recommended for benign meningioma patients, while adjuvant radiotherapy is routinely recommended for malignant meningioma patients (WHO grade III) (6). But there is still a controversy for atypical meningioma (AM) patients because of the unclear effectiveness of PORT. Several studies with small sample sizes have been performed to investigate the effect of PORT in AM patients after GTR, but obtained contradictory results (7–25). A recent study based on the National Cancer Database found that PORT and GTR were both associated with improved survival for AM patients (26). Whereas our recent study based on the Surveillance, Epidemiology, and End Results database found that PORT might not prolong the overall survival (OS) in AM patients undergoing GTR (27).

Hasan et al. published a meta-analysis concerning the efficacy of PORT after GTR on AM patients in 2014 (28). That study showed that for the enrolled 757 patients, PORT significantly reduced the risk of recurrence and increased the local control rate for 5 years, but did not reduce the overall mortality (28). However, the articles included in this meta-analysis were published between 1993 and 2013. Besides, they did not analyze the impact of PORT on progression-free survival (PFS), which is also an important prognostic indicator. With the great modifications in the 2000 WHO classification criteria for meningioma and a large number of articles focused on the prognosis of AM patients after GTR in recent years, it is necessary to summarize them again. The aim of this study was to systematically review and meta-analyze the effectiveness of PORT in AM patients after GTR.

MATERIALS AND METHODS

Literature Search and Study Selection

A systematic review of the literatures on the relationship between PORT and the prognosis of AM patients after GTR between January 2000 and January 2019 in the Pubmed, Embase, Web of science, and Scopus databases was performed. The search of published articles was undertaken using the following terms: “gross total resection,” “atypical meningioma” or “grade II meningioma” and “radiotherapy.”

The excluding criteria are listed as below: (1) research subjects were not well defined, such as AM patients including benign meningioma patients or malignant meningioma patients, and GTR patients including STR patients; (2) the efficacy of PORT after GTR on AM patients was not compared; (3) AM was defined according to the WHO classification criteria before the year 2000; (4) the 5-year prognostic data were not available; (5) non-English literatures or literatures of systematic reviews, case reports, observational studies; (6) database-based researches.

Data Extraction and Quality Assessment

Two investigators extracted data from the relevant articles independently. If the opinions or data were inconsistent, they would discuss until consensus were reached. Extracted data should include: name, year of publication, the type of study, WHO classification criteria, the number of cases, age, gender, the grade of meningioma, degree of surgical resection, PORT, and the treatment endpoint. GTR was defined as Simpson grade I–III in this study.

Newcastle-Ottawa Scale (NOS) literature quality assessment scale and revised standards were used to assess quality of included articles. The evaluation scales were based on the following three indicators: patient selection, study comparability, and research outcome. The score was 9 points in total, the article with 6 points or more was considered as high-quality.

Statistical Analysis

The patients were divided into two groups, patients received GTR plus PORT and patients received GTR without PORT. Because of the cumulative survival rates, we performed a meta-analysis by converting that to the assumed cumulative number of survivors. Odds ratios (ORs) with 95% confidence interval (CI) were utilized to evaluate the difference in 5-year local control (LC) rate, 5-year PFS rate, and 5-year OS rate between the two groups. Heterogeneity of pooled results was assessed using Cochrane’s Q test and $I^2$ measurement. $P > 0.10$ or $I^2 < 50\%$ indicated that the heterogeneity was not significant, and then a fixed-effects model was used. Otherwise, a random effect model was used. Sensitivity analysis was conducted to evaluate the validity and reliability of present meta-analysis. Begg’s funnel plot and Egger’s test were used to evaluate the publication bias risk. All statistical analyses were performed using STATA version 15.1 (STATA Corporation, College Station, TX, USA), and all P values were two sides.
meet research topics, 50 articles were initially included. By reading the full text, 33 articles were excluded according to the excluding criteria. Finally, a total of 17 articles were included in this meta-analysis.

The basic characteristics of the final included studies were shown in Table 1. The data included the author, the year of publication, the country, the year of treatment, the WHO classification standard, the type of study, the sample data, and the survival rate. A total of 2,008 AM patients were included in the 17 articles. Among them, 1,492 patients did not receive PORT after GTR and 369 patients received PORT after GTR.

According to the NOS literature quality evaluation scale and revised standards, the included literatures were evaluated. As shown in Table 1, the quality of the literatures was generally high (6–9 points).

**Effectiveness of Postoperative Adjuvant Radiotherapy on 5-Year Progression-Free Survival**

Twelve articles reported the effect of PORT on 5-year PFS in AM patients after GTR. One of the articles suggested that PORT significantly improved 5-year PFS (14), but 11 articles found that PORT had no significant relationship with 5-year PFS. Integrating the above literature data for analysis, 662 AM patients did not receive PORT after GTR, and 276 patients received PORT after GTR. There was no significant difference in heterogeneity analysis ($I^2 = 42.6\%, P = 0.058$). The 5-year PFS was 84.1% in the patients receiving PORT and 71.9% for those not. The meta-analysis showed that PORT could significantly improve 5-year PFS in AM patients after GTR (OR [95% CI] = 1.99 [1.35–2.95], $P = 0.001$) (Figure 2A). Figure 2B indicated that there was no significant publication bias ($P = 0.075$). The sensitive analysis was performed by removing studies one by one, and the removal of any individual study did not affect its overall trend, indicating that the results of this meta-analysis were stable and reliable (Figure 2C).

**Effectiveness of Postoperative Adjuvant Radiotherapy on 5-Year Overall Survival**

Five articles reported the effect of PORT on 5-year OS in AM patients after GTR. None of them found that PORT could significantly improve 5-year OS. Among them, 353 AM patients did not receive PORT after GTR, and 114 patients received PORT after GTR. There was no significant difference in heterogeneity analysis ($I^2 = 0\%, P = 0.931$). The 5-year OS was 79.0% in the patients receiving PORT and 81.5% in those not. The meta-analysis showed that PORT had no significant relationship with 5-year OS (OR [95% CI] = 1.07 [0.60–1.91], $P = 0.828$) (Figure 3A). Figure 3B indicated that there was no significant publication bias ($P = 0.142$). The sensitive analysis was performed by removing studies one by one, and the removal of any individual study did not affect its overall trend, indicating that the results of this meta-analysis were stable and reliable (Figure 3C).

**Effectiveness of Postoperative Adjuvant Radiotherapy on 5-Year Local Control**

Six articles reported the effect of PORT on 5-year LC in AM patients after GTR. Heterogeneity analysis found significant differences between two groups. Begg’s funnel plot and Egger’s test showed that there was a clear publication bias in an article (Figures 4A, B). The sensitive analysis was performed by removing studies one by one, and the Charles Champeaux’s was significantly heterogeneous, so it was excluded. Remaining articles had no heterogeneity ($I^2 = 0\%, P = 0.460$) (Figure 5B). The 5-year LC was 82.2% in the patients receiving PORT and 71.0% for those not. The meta-analysis showed that PORT could significantly improve 5-year LC (OR [95% CI] = 2.59 [1.40–4.81], $P = 0.002$) (Figure 5A). There was no significant publication bias ($P = 0.142$) and the results were stable and reliable (Figure 5C).

**DISCUSSION**

At present, optimal postoperative management for AM patients after GTR remains a great deal of controversy. The NCCN Guideline recommends radiotherapy in several situations (29), but there is no conclusion on whether radiotherapy is needed for AM patients after GTR. In the current study, we found that PORT could improve the 5-year LC rate and 5-year PFS rate in...
TABLE 1 | Characteristics of studies for association between PORT and survival.

| Author/year of publication/country | Year of treatment | WHO classification criteria | Year of treatment | Type of study | No. of case | Sex(male/female) | Age (year) | Follow-up time (month) | GTR definition | No. of GTR | No. of PORT | Indicator | NOS |
|-----------------------------------|------------------|-----------------------------|------------------|--------------|------------|----------------|------------|----------------------|----------------|-----------|-------------|-----------|-----|
| Manish K. Aghi/2009/USA (8)       | 1993–2004        | Retrospective cohort study  | 2000             | Retrospective cohort study | 108        | 48/69          | 55 (19–82) | 39 (1–168)            | Simpson grade I resection | 80        | 8           | OR, 5-year | 8/9 |
| Kyungil Jo/2010/Korea (9)         | 1997–2008        | Retrospective cohort study  | 2000             | Retrospective cohort study | 35         | 18/17          | 56 (15–90) | 40 (6–97)             | Simpson grade I resection | 32        | 19          | OR, 5-year | 7/9 |
| Kangmin D. Lee/2013/USA (10)     | 1999–2009        | Retrospective cohort study  | 2007             | Retrospective cohort study | 90         | 34/56          | 56.9 (22–83) | 48.7 (12–108)         | Simpson grade I–III resection | 71        | 17          | OR, 5-year | 8/9 |
| Sam Q. Sun/2014/USA (11)         | 1993–2012        | Retrospective cohort study  | 2007             | Retrospective cohort study | 151        | 63/88          | 54 (8.8–86.2) | 45 (6–232)            | Simpson grade I–III resection | 151       | 39          | OR, 5-year | 8/9 |
| Michael D. Jenkinson/2016/UK (12) | 2001–2010       | Retrospective cohort study  | 2000/2007        | Retrospective cohort study | 133        | 68/65          | 62 (22–86) | 57.4 (0.1–152.2)      | Simpson grade I–III resection | 113       | 32          | OR, 5-year | 8/9 |
| Christopher S. Graffeo/2017/USA (13) | 1988–2016      | Retrospective cohort study  | 2007             | Retrospective cohort study | 69         | 25/44          | 61 (27–91) | 69 (5.2–273.5)        | Simpson grade I–III resection + no residue in image | 69        | 8           | OR, 5-year | 7/9 |
| Shakir I. Shakir/2018/Canada (14) | 1992–2013       | Retrospective cohort study  | 2007             | Retrospective cohort study | 70         | 32/38          | 62 (32–87) | 69 (5.2–172)          | Simpson grade I resection | 40        | 12          | OR, 5-year | 8/9 |
| Salah Hammouche/2014/UK (15)     | 1996–2009        | Retrospective cohort study  | 2007             | Retrospective cohort study | 79         | 43/36          | 58 ± 13.6 | 50 (1–172)           | Simpson grade I resection | 34        | 9           | OR, 5-year | 7/9 |
| Hae Jin Park/2013/USA (16)       | 1997–2011        | Retrospective cohort study  | 2000/2007        | Retrospective cohort study | 83         | 33/50          | 52 (24–78) | 43 (6.2–160.0)        | Simpson grade I–II resection | 55        | 17          | 5-year PFS | 7/9 |
| Richard Mair/2011/UK (17)        | 2001–2010        | Retrospective cohort study  | 2000             | Retrospective cohort study | 114        | 55/59          | 57 (17–85) | NR                   | Simpson grade I–II resection | 66        | 15          | 5-year PFS | 7/9 |
| Ming Zhi/2018/USA (18)           | 2002–2012        | Retrospective cohort study  | 2000/2007        | Retrospective cohort study | 149        | 74/75          | 64 (18–91) | 74.2(0.5–182.2)       | Simpson grade I–III resection | 98        | 26          | OR, 5-year | 8/9 |
| Ammoren Dohma/2017/USA (19)      | 1993–2014        | Retrospective cohort study  | 2007             | Retrospective cohort study | 115        | 45/70          | 63.8 ± 14.7 | NR                   | Simpson grade I–III resection | 78        | 41          | OR, 5-year | 8/9 |
| Karol P. Budhoski/2018/UK (20)   | 2007–2014        | Retrospective cohort study  | 2016             | Retrospective cohort study | 220        | 98/122         | 61(50–68) | NR                   | Simpson grade I–III resection | 143       | 35          | OR         | 6/9 |
| Hannah Yoon/2015/USA (21)       | 2000–2010        | Retrospective cohort study  | 2000             | Retrospective cohort study | 158        | 72/86          | 58 (19–90) | NR                   | Simpson grade I–III resection | 109       | 7           | 5-year OS | 7/9 |
| Yu-Chi Wang/2014/China (22)      | 2001–2009        | Retrospective cohort study  | 2007             | Retrospective cohort study | 28         | 13/15          | 56.8 (23–85) | 57.4 (16–144)        | Simpson grade I–III resection + no residue in image | 14        | 3           | 5-year PFS | 8/9 |
| Charles Champeaux/2016/UK (23)   | 2000–2015        | Retrospective cohort study  | 2007             | Retrospective cohort study | 178        | 81/97          | 57 (44.7–68.8) | 43.2 (18–74.4)       | Simpson grade I–III resection | 127       | 24          | 5-year LC | 8/9 |
| Douglas A. Hardesty/2013/USA (24) | 1992–2011       | Retrospective cohort study  | 2007             | Retrospective cohort study | 228        | 97/131         | 62(2–94)      | 52                   | Simpson grade I–III resection | 149       | 72          | 5-year PFS | 7/9 |

OR, overall number of recurrence.
AM patients after GTR, indicating that AM patients might benefit from PORT after GTR. PORT plays an important role in post-operative management of AM patients. It was showed that patients without PORT after STR had worse PFS (16). Recently, Chenyang Wang et al. (30) found that PORT could significantly improve OS in AM patients who underwent STR (30), which was consistent with our previous finding (27). Currently, PORT has been routinely recommended for AM patients who underwent STR (6, 31).

However, it is contentiously debated whether AM patients can benefit from PORT after GTR. In recent years, a large number of studies have been conducted to find out whether PORT has an effect on the prognosis of AMs after GTR, but lead to contradictory conclusions. Recently, Shakir et al. performed a single-center retrospective study and reported that PORT could improve the 5-year PFS rate in AM patients after GTR (14). However, many studies revealed the ineffectiveness of PORT on AMs after GTR, although most of them showed that PORT had a trend to improve the 5-year PFS rate (11, 13, 15, 17–19, 22, 24). The non-significant differences may due to the relatively small sample sizes of these studies. Therefore, we performed this meta-analysis with a total of 2,008 AMs enrolled to overcome this limitation. The results showed that PORT could significantly improve 5-year PFS rate and 5-year LC, indicating that AMs can benefit from PORT after GTR.

A previous meta-analysis by Hasan et al., including 14 retrospective studies reported from 1984 to 2012, found that PORT for AM patients might decrease risk for relapse (28). However, the WHO classification standard for meningiomas was greatly modified in 2000. Therefore, the literatures enrolled in the current study were all using 2000 WHO classification criteria or later, and the literatures using WHO classification criteria before 2000 or without identified WHO classification criteria were all excluded. In some degree, our study might reduce sample selection bias. Therefore, we considered it was meaningful to conduct this meta-analysis to show that AM patients could benefit from PORT after GTR, which was in line with that previous meta-analysis.

As reported in the previous literatures, many types of radiotherapy, such as conventional radiotherapy, single-fraction stereotactic radiosurgery, fractionated stereotactic radiotherapy, three-dimensional conformal radiotherapy and intensity modulated radiotherapy, have been conducted in AM patients after GTR (8, 16, 18, 24). However, most of the enrolled articles did not compare the differences in the treating effect among different radiotherapy methods. At present, it still remains

---

**FIGURE 2** | (A) Forest plot for the relationships between PORT and 5-year PFS. (B) Begg’s funnel plots of publication bias for meta-analysis of PORT. (C) Sensitivity analysis for meta-analysis of PORT.
unclear which type of radiotherapy is preferred for AM patients after GTR. Further studies are needed to investigate the effect of different types of PORT, which might guide the selection of PORT type for radiotherapist.

Our study also has several limitations. First, all enrolled articles are retrospective single-center studies (8–24), and inherent limitations exist in this kind of studies, such as selection bias. Second, the WHO classification criteria (13) and the definition of GTR (8, 9, 15–17) are somewhat different among the articles which may also lead to bias. Third, in the current meta-analysis, we could not perform multivariable analysis including other factors, such as MIB-1 index, location, brain edema, and several molecular markers, which might also influence tumor behavior and recurrence rate. Forth, we chose 5-year PFS, LC, and OS as the prognostic indicators, because most of previous studies did not reported the rates of PFS, LC, and OS with a longer time. The non-significant effect of PORT on OS in our study might due to the short follow-up time. Thus, a longer window than 5 years might be more effective at teasing out potential advantages of PORT on OS. Further studies with a longer follow-up time are warrant. Thus, further multi-center prospective studies of a large sample size with a panel of these markers and longer follow-up time are needed to confirm our findings. Currently, two phase-III clinical trials, ROAM-EORTC

FIGURE 3 | (A) Forest plot for the relationships between PORT and 5-year OS. (B) Begg’s funnel plots of publication bias for meta-analysis of PORT. (C) Sensitivity analysis for meta-analysis of PORT.

FIGURE 4 | (A) Begg’s funnel plots of publication bias for meta-analysis of PORT on 5-year LC before excluding. (B) Sensitivity analysis for meta-analysis of PORT.
1308 and NRG-BN003, are now ongoing to investigate whether AM patients can benefit from PORT after GTR.

CONCLUSION

This meta-analysis showed that PORT could significantly improve 5-year LC and 5-year PFS in AM patients after GTR, indicating that AM patients may benefit from PORT after GTR. The results from two ongoing phase-III clinical trials (ROAM-EORTC 1308 and NRG-BN003) will further help to address the controversy about the effectiveness of PORT in atypical meningioma patients after GTR.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

This work was supported by the National Natural Science Foundation of China (81801654) and Zhejiang Provincial Natural Science Foundation (LY20H160037).

REFERENCES

1. Ostrom QT, Gittleman H, Blank PMD. American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncology (2016) 1(suppl 1):i1. doi: 10.1093/neuonc/nov297

2. Louis DN, Perry A, Reifenberger G. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol (2016) 131(6):803–20. doi: 10.1007/s00401-016-1545-1

3. Rogers L, Barani I, Chamberlain M. Meningiomas: Knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg (2015) 122(1):4–23. doi: 10.3171/2014.7.JNS131644
4. Yang SY, Park CK, Park SH. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. *J Neurol Neurosurg Psychiatry* (2008) 79(5):574–80. doi: 10.1136/jnnp.2007.121582
5. Palma L, Celli P, Franco C. Long-term prognosis for atypical and malignant meningiomas: A study of 71 surgical cases. *J Neurol Neurosurg Psychiatry* (1997) 65(5):793–800. doi: 10.1136/jns.1997.65.5.7973
6. Goldbrunner R, Minniti G, Preusser M. EANO guidelines for the diagnosis and treatment of meningiomas. *Lancet Oncol* (2016) 17(9):e383–91. doi: 10.1016/S1470-2045(16)30321-7
7. Masalha W, Heiland DH, Franco P. Atypical meningioma: Progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiosurgery. *J Neuro Oncol* (2018) 136:147–54. doi: 10.1007/s11060-017-2634-z
8. Aghi MK, Carter BS, Cosgrove GR. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. *Neurosurgery* (2009) 64(1):56. doi: 10.1227/01.NEU.0000330399.55866.63
9. Jo K, Park HJ, Nam DH. Treatment of atypical meningioma. *J Clin Neurosci* (2010) 17(11):1362–6. doi: 10.1016/j.jocn.2010.03.036
10. Lee KD, Depewell JJ, Air EL. Atypical meningiomas: Is postoperative radiotherapy indicated? *Neurosurg Focus* (2013) 35(6):E15. doi: 10.3171/2013.9.FOCUS133325
11. Sun SQ, Kim AH, Cai C. Management of atypical cranial meningiomas: part 1: predictors of recurrence. *Neurosurgery* (2014) 75(4):347–54. doi: 10.1227/NEU.0000000000000461
12. Jenkinson MD, Waqar M, Farah JO. Early adjuvant radiotherapy in the treatment of atypical meningioma. *J Clin Neurosci* (2016) 28:87–92. doi: 10.1016/j.jocn.2015.09.021
13. Grafeo CS, Leeper HE, Perry AA. Revisiting adjuvant radiotherapy following gross total resection of WHO grade II meningioma. *World Neurosurg* (2017) 103:655–63. doi: 10.1016/j.wneu.2016.01.055
14. Shakir SI, Souhami L, Petrecca K. Prognostic factors for progression in atypical meningioma. *J Neurosurg* (2018) 129:1240–8. doi: 10.3171/2017.6.JNS17120
15. Hammouche S, Clark S, Wong AHL. Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment. *Acta Neurochirurgica* (2014) 156(8):1475–81. doi: 10.1007/s00701-014-2156-z
16. Hae JP, Hyun-Cheol K, Il HK. The role of adjuvant radiotherapy in atypical meningioma. *J Neuro-oncol* (2013) 115(2):241–7. doi: 10.1007/s11060-013-1219-y
17. Mair R, Morris K, Scott I. Radiotherapy for atypical meningiomas. *J Neuro-oncol* (2011) 115(4):819–9. doi: 10.1007/s11060-013-1219-y
18. Zhi M, Girvigian MR, Miller MJ. Long-term outcomes of newly diagnosed resected atypical meningiomas and the role of adjuvant radiotherapy. *World Neurosurg* (2019) 122:e153–61. doi: 10.1016/j.wneu.2018.11.006
19. Dohn A, McTyer ER, Chan MD. Early or late radiotherapy following gross or subtotal resection for atypical meningioma: Clinical outcomes and local control. *J Clin Neurosci* (2017) 46:90–8. doi: 10.1016/j.jocn.2017.08.023
20. Budohoski KP, James C, Millward CP. Predictors of early progression of surgically treated atypical meningiomas. *Acta Neurochirurgica* (2018) 160:1813–22. doi: 10.1007/s00701-018-3593-x
21. Yoon H, Mehta MP, Perumal K. Atypical meningioma: Randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. *J Cancer Res Ther* (2015) 11(1):59. doi: 10.4103/0973-1482.148708
22. Wang YC, Chuang CC, Wei KC. Skull base atypical meningioma: Long term surgical outcome and prognostic factors. *Clin Neurol Neurosurg* (2015) 128:112–6. doi: 10.1016/j.clinuero.2014.11.009
23. Champeaux C, Dunn L. World Health Organization grade II meningioma. A 10-year retrospective study for recurrence and prognostic factor assessment. *World Neurosurg* (2016) 89:180–6. doi: 10.1016/j.wneu.2016.01.055
24. Hardesty DA, Wolf AB, Brachman DG. The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical Resection. *J Neurosurg* (2013) 119:475–81. doi: 10.3171/2012.12.JNS121414
25. Bagphaw HP, Burt LM, Jensen RL. Adjuvant radiotherapy for atypical meningiomas. *J Neurosurg* (2016) 126:1822–8. doi: 10.1017/176.5.JNS152809
26. Rydzewski NR, Lesniak MS, Chandler JP, Kalapurakal JA, Pollom E, Tate MC. Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma. *Cancer* (2018) 124:734–42. doi: 10.1002/cncr.31088
27. Zeng Q, Shi F, Guo Z. Effectiveness of postoperative radiotherapy on atypical meningioma patients: A population-based study. *Front Oncol* (2019) 9:34. doi: 10.3389/fonc.2019.00034
28. Hasan S, Young M, Albert T. The role of adjuvant radiotherapy after gross total resection of atypical meningiomas. *World Neurosurg* (2018) 83(5):808–15. doi: 10.1016/j.wneu.2014.12.037
29. Nabors LB, Portnow J, Ammirati M. NCCN guidelines insights: central nervous system cancers, version 1.2017. *J Natl Compr Canc Netw* (2017) 15(11):1331–45. doi: 10.6004/jnccn.2017.0166
30. Wang C, Kaprelian TB, Suh JH, Kubicky CD, Ciporen JN, Chen Y, et al. Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. *Neuro Oncol* (2017) 19(9):1263–70. doi: 10.1093/neuroon/xox007
31. Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. *Expert Rev Neurother* (2018) 18:241–9. doi: 10.1080/14737175.2018.1429920

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 He, Zhang, Zhang, Guo, Shi and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.